Search bioRxivSearch

Biology subjects

Bhattarai, S.

Publications and source records attributed to Bhattarai, S..

2 recordsLinked to original sources

Mechanisms of γ-Secretase Activation and Substrate Processing

Amyloid {beta}-peptide, the principal component of characteristic cerebral plaques of Alzheimers disease (AD), is produced through intramembrane proteolysis of the amyloid precursor protein (APP) by {gamma}-secretase. Despite the importance in pathogenesis of AD, the mechanisms of intramembrane proteolysis and substrate processing by {gamma}-secretase remain poorly understood. Here, complementary all-atom simulations using a robust Gaussian accelerated molecular dynamics (GaMD) method and biochemical experiments were combined to investigate substrate processing of wildtype and mutant APP by {gamma}-secretase. The GaMD simulations captured spontaneous activation of {gamma}-secretase, with hydrogen bonded catalytic aspartates and water poised for proteolysis of APP at the {varepsilon} cleavage site. Furthermore, GaMD simulations revealed that familial AD mutations I45F and T48P enhanced the initial {varepsilon} cleavage between residues Leu49-Val50, while M51F mutation shifted the {varepsilon} cleavage site to the amide bond between Thr48-Leu49. Detailed analysis of the GaMD simulations allowed us to identify distinct low-energy conformational states of {gamma}-secretase, different secondary structures of the wildtype and mutant APP substrate, and important active-site sub-pockets for catalytic function of the enzyme. The simulation findings were highly consistent with experimental analyses of APP proteolytic products using mass spectrometry and western blotting. Taken together, the GaMD simulations and biochemical experiments have enabled us to elucidate the mechanisms of {gamma}-secretase activation and substrate processing, which should facilitate rational computer-aided drug design targeting this functionally important enzyme.

biochemistry

Transcriptomic profiling of plaque psoriasis and cutaneous T cell subsets during treatment with secukinumab

The IL17A inhibitor secukinumab is efficacious for the treatment of psoriasis. In order to define its mechanism of action, it is important to understand its impact on psoriatic whole skin tissue as well as specific skin-resident immune cell populations such as T lymphocytes. In this study, we treated 15 moderate-to-severe plaque psoriasis patients with secukinumab and characterized the longitudinal transcriptomic changes of whole lesional skin tissue and cutaneous CD4+ T effector cells (Teffs), CD4+ T regulatory cells (Tregs), and CD8+ T effector cells during 12 weeks of treatment. Secukinumab was clinically effective, with 100%, 47%, and 27% of patients in the study achieving PASI75, PASI90, and PASI100 by week 12, respectively. At baseline prior to treatment, we observed that IL17A overexpression predominates in psoriatic CD8+ T cells rather than Teffs, supporting the importance of IL-17-secreting CD8+ T cells (Tc17) compared to IL-17-secreting CD4+ T cells (Th17) cells in the pathogenesis of psoriasis. Although secukinumab targets only IL17A, we observed rapid reduction of IL17A, IL17F, IL23A, IL23R, and IFNG expression in lesional skin as soon as 2 weeks after initiation of treatment and normalization of expression by week 12. Secukinumab treatment resulted in resolution of 89-97% of psoriasis-associated expression differences in both bulk tissue and T cell subsets by week 12 of treatment. Overall, secukinumab appears to rapidly reverse many of the molecular hallmarks of psoriasis.

genomics